CHINARES PHARMA's innovative drug "Huasike" has obtained exclusive rights for development, production, and commercialization in China

AASTOCKS
2025.11.10 09:42

China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources Sanjiu (000999.SZ) has signed an agreement with Langyu Group and Bioproject, officially obtaining the exclusive rights for the development, production, and commercialization of the innovative drug "Huasu" (Tilidine Tablets) held by Langyu Group in China.

Huasu is the first innovative drug approved in China for the treatment of narcolepsy and is the first and currently the only non-controlled substance for this disease. It has received a Class I recommendation and Class A evidence for the symptoms of excessive daytime sleepiness, cataplexy, sleep hallucinations, and sleep paralysis in the "four syndromes." It is also recommended in guidelines in countries such as the United States and Europe, filling the gap in clinical medications for narcolepsy in China. Additionally, the indication for obstructive sleep apnea for Huasu has been approved in Europe

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer